Market Overview

Bristol-Myers Squibb Says Orencia Approved by EU

Share:
Related BMY
Analyst's Key Takeaways From Eli Lilly, Bristol-Myer Squibb's Latest Conference Calls
Bristol-Myers Squibb Posts Upbeat Q2 Results, Lifts Profit Forecast
Big Pharma Tops Q1 Earnings & Revenue: ETFs in Focus - ETF News And Commentary (Zacks)

Bristol-Myers Squibb announced today that the European Commission has granted marketing authorisation for the subcutaneous formulation of ORENCIA ® (abatacept), in combination with methotrexate (MTX), for the treatment of adults with moderate to severe active rheumatoid arthritis (RA).

Posted-In: News FDA

 

Related Articles (BMY)

Get Benzinga's Newsletters